Dividend Declaration
DESJARDINS RI USA LOW CO2 INDEX ETF UNITS
$36.85
11:15 24/04/24
08 May 2019
Animalcare Group plc
("Animalcare" or the "Group")
Dividend declaration for the 12 months ended 31 December 2018
Animalcare Group plc (AIM: ANCR), the pan-European Animal Health business, is pleased to announce that, subject to shareholder approval at its Annual General Meeting on Tuesday 25 June 2019, it will pay a final dividend of 2.4 pence per share, adding to the interim dividend of 2.0 pence per share paid in November 2018, giving a total dividend of 4.4 pence per share for the year ended 31 December 2018. The final dividend of 2.4 pence per share will be paid on Friday 5 July 2019 to shareholders whose names are on the Register of Members at close of business on 7 June 2019. The ordinary shares will become ex-dividend on Thursday 6 June 2019.
For further information, please contact:
Animalcare Group plc | Tel: 01904 487 687 | |
Jenny Winter, Chief Executive Officer |
| |
Chris Brewster, Chief Financial Officer |
| |
|
| |
Panmure Gordon (UK) Ltd (Nominated Adviser and Broker) | Tel: 020 7886 2500 | |
Corporate Finance Freddy Crossley / Emma Earl Corporate Broking James Stearns |
| |
|
| |
Consilium Strategic Communications | Tel: 020 3709 5700 or [email protected] | |
Amber Fennell |
| |
Jonathan Birt |
| |
Angela Gray Olivia Manser |
| |
About Animalcare (www.Animalcaregroup.co.uk)
Animalcare Group plc is a UK AIM listed veterinary sales and marketing organisation resulting from the merger of Animalcare and Ecuphar NV in July 2017. Animalcare operates in 32 countries in Europe and a further 16 worldwide. The company is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.